Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4737789 | 0.83 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL13685884 | 0.81 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL7657871 | 0.80 | ALDH1A1 (0.54) | ALDH1A1 | |
| SCHEMBL10157907 | 0.79 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL7663993 | 0.78 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL7670645 | 0.78 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL2015730 | 0.72 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL2220993 | 0.72 | ALDH1A1 (0.62) | ALDH1A1 | |
| SCHEMBL7759159 | 0.72 | — | — | |
| SCHEMBL9803543 | 0.72 | ALDH1A1 (0.62) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4175943-B1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS BEIJING CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-11987556-B2 | Dual-functional compounds and methods of use | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-05-21 | — | — | US | disclosed |
| US-20230174482-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2023-06-08 | — | — | US | disclosed |
| EP-4175943-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | Biofront Therapeutics (Beijing) Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023005180-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022022669-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2022-02-03 | — | — | WO | disclosed |
| CN-113767104-A | Bifunctional compounds and methods of use thereof | 百放英库医药科技(北京)有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-7595313-B2 | Nitric oxide donating diuretic compounds, compositions and methods of use | NICOX, S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| US-7595313-B2 | Nitric oxide donating diuretic compounds, compositions and methods of use | NICOX, S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-4801596-A | Nitroxy amino propanols for treating heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1989-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174482-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | PDE1A, PDE3B, PDE1B | ALDH1A1 471/4885 |
| US-11987556-B2 | Dual-functional compounds and methods of use | PDE1A, PDE3B, PDE1B | ALDH1A1 471/4885 |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS1, NOS3, NOS2 | ALDH1A1 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.